Literature DB >> 20167321

Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer.

Solange Maria Diniz Bizzo1, Débora Dummer Meira, José Marinaldo Lima, Jânio da Silva Mororó, José Cláudio Casali-da-Rocha, Maria Helena Faria Ornellas.   

Abstract

OBJECTIVE: To determine whether peripheral plasma concentration, peritoneal fluid concentration, and/or peritoneal vascular endothelial growth factor (VEGF) burden can predict the possibility of optimal cytoreduction in women with epithelial ovarian carcinoma (EOC); and if so, to determine cutoff values below which optimal cytoreduction is likely to occur.
METHODS: We measured plasma VEGF concentration, peritoneal VEGF concentration, and VEGF burden in 46 women undergoing cytoreductive surgery. Univariate analysis, bivariate analysis, correlation tests, and stepwise regression were performed with cytoreduction as the outcome.
RESULTS: The VEGF burden best predicted the outcome. The area under the curve was 0.84 and the log-transformed cutoff value was 15.52 log pg. Overall, the chance of optimal cytoreduction was 11 times greater when the VEGF burden was less than 15.52 log pg. For women with advanced disease, the chance was 6 times greater below this value.
CONCLUSION: The VEGF burden may quantify tumor activity, and it could be used when selecting patients likely to benefit from induction chemotherapy before undergoing cytoreductive surgery. Copyright 2009 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167321     DOI: 10.1016/j.ijgo.2009.11.021

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  7 in total

1.  P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression.

Authors:  Chuan-Xiu Bian; Zhumei Shi; Qiao Meng; Yue Jiang; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Biochem Biophys Res Commun       Date:  2010-06-25       Impact factor: 3.575

2.  HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma.

Authors:  Cecilia Midulla; Lucia Manganaro; Flavia Longo; Valentina Viggiani; Luigi Frati; Teresa Granato; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-03-20

3.  Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model.

Authors:  Guillaume Passot; Aurélien Dupré; Michel Rivoire; Faheez Mohamed; Naoual Bakrin; Olivier Glehen
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

4.  Anacardic acid enhances the proliferation of human ovarian cancer cells.

Authors:  Yin-Ling Xiu; Yang Zhao; Wen-Feng Gou; Shuo Chen; Yasuo Takano; Hua-Chuan Zheng
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

5.  Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  N R Sluiter; E M V de Cuba; R Kwakman; W J H J Meijerink; P M Delis-van Diemen; V M H Coupé; J A M Beliën; G A Meijer; I H J T de Hingh; E A te Velde
Journal:  Clin Exp Metastasis       Date:  2016-02-12       Impact factor: 5.150

6.  Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.

Authors:  E M V de Cuba; I H J T de Hingh; N R Sluiter; R Kwakman; V M H Coupé; J A M Beliën; V J Verwaal; W J H J Meijerink; P M Delis-van Diemen; H J Bonjer; G A Meijer; E A Te Velde
Journal:  Ann Surg Oncol       Date:  2016-01-04       Impact factor: 5.344

7.  Correlation of the expression of vascular endothelial growth factor and its receptors with microvessel density in ovarian cancer.

Authors:  Limei Wang; Xiaoyan Liu; Hong Wang; Shuhe Wang
Journal:  Oncol Lett       Date:  2013-05-15       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.